Skip to main content
SpringerLink
Log in
Book cover

Adenosine pp 409–434Cite as

Adenosine Receptors in Huntington’s Disease

  • Chapter
  • First Online:

Abstract

Huntington’s disease is a devastating hereditary neurodegenerative disorder caused by CAG mutation within the IT15 gene encoding Huntingtin protein. Even though mutant and normal Huntingtin are ubiquitously expressed, the degenerative processes primarily occur within the striatum and particularly hit the GABAergic enkephalin neuronal subpopulation of medium spiny neurons particularly enriched with adenosine A2ARs, suggesting that the latter might play a role in HD. In agreement, variants in the ADORA2A gene influence the age at onset in HD and A2AR dynamics is largely altered by mutated Huntingtin. Adenosine receptors are involved in a number of processes critical for neuronal function and homeostasis, such as modulation of synaptic activity and excitotoxicity, the control of neurotrophin levels and functions as well as the regulation of protein degradation mechanisms. In the present review, we critically reviewed the current knowledge involving adenosine receptors in HD and discussed whether they represent a suitable therapeutic target.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alberch J, Lopez M, Badenas C, Carrasco JL, Mila M, Munoz E, Canals JM (2005) Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology 65:964–965

    Article  CAS  PubMed  Google Scholar 

  • Alfinito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23:10982–10987

    CAS  PubMed  Google Scholar 

  • Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28:1694–1702

    Article  CAS  PubMed  Google Scholar 

  • Andre VM, Cepeda C, Fisher YE, Huynh M, Bardakjian N, Singh S, Yang XW, Levine MS (2011) Differential electrophysiological changes in striatal output neurons in Huntington’s disease. J Neurosci 31:1170–1182

    Article  CAS  PubMed  Google Scholar 

  • Andresen JM, Gayan J, Djousse L, Roberts S, Brocklebank D, Cherny SS, Cardon LR, Gusella JF, MacDonald ME, Myers RH et al (2007) The relationship between CAG repeat length and age of onset differs for Huntington’s disease patients with juvenile onset or adult onset. Ann Hum Genet 71:295–301

    Article  CAS  PubMed  Google Scholar 

  • Bantubungi K, Blum D (2007a) Mechanisms of neuronal death in Huntington’s disease. First part: general considerations and histopathological features. Rev Med Brux 28:413–421

    CAS  PubMed  Google Scholar 

  • Bantubungi K, Blum D (2007b) Mechanisms of neuronal death in Huntington’s disease. Second part: therapeutic challenges. Rev Med Brux 28:487–494

    CAS  PubMed  Google Scholar 

  • Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321:168–171

    Article  CAS  PubMed  Google Scholar 

  • Benarroch EE (2008) Brain cholesterol metabolism and neurologic disease. Neurology 71:1368–1373

    Article  PubMed  Google Scholar 

  • Benchoua A, Trioulier Y, Diguet E, Malgorn C, Gaillard MC, Dufour N, Elalouf JM, Krajewski S, Hantraye P, Deglon N et al (2008) Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet 17:1446–1456

    Article  CAS  PubMed  Google Scholar 

  • Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P et al (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652–1663

    Article  CAS  PubMed  Google Scholar 

  • Blum D, Galas MC, Gall D, Cuvelier L, Schiffmann SN (2002a) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington’s disease. Neurobiol Dis 10:410–426

    Article  CAS  PubMed  Google Scholar 

  • Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, Muller CE, Bantubungi K, Galluzzo M, Gall D, Cuvelier L et al (2003a) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci 23:5361–5369

    CAS  PubMed  Google Scholar 

  • Blum D, Gall D, Galas MC, d’Alcantara P, Bantubungi K, Schiffmann SN (2002b) The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 22:9122–9133

    CAS  PubMed  Google Scholar 

  • Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN (2003b) Adenosine receptors and Huntington’s disease: implications for pathogenesis and therapeutics. Lancet Neurol 2:366–374

    Article  CAS  PubMed  Google Scholar 

  • Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000) Synaptic organisation of the basal ganglia. J Anat 196(Pt 4):527–542

    Article  CAS  PubMed  Google Scholar 

  • Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116:1410–1424

    Article  CAS  PubMed  Google Scholar 

  • Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 106:22480–22485

    Article  CAS  PubMed  Google Scholar 

  • Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, Li XJ (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 285:10653–10661

    Article  CAS  PubMed  Google Scholar 

  • Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington’s disease phenotype in experimental animals. Prog Neurobiol 59:427–468

    Article  CAS  PubMed  Google Scholar 

  • Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J Neurochem 95:1521–1540

    Article  CAS  PubMed  Google Scholar 

  • Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646–653

    Article  CAS  PubMed  Google Scholar 

  • Buira SP, Albasanz JL, Dentesano G, Moreno J, Martin M, Ferrer I, Barrachina M (2010a) DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. J Neurochem 112:1273–1285

    Article  CAS  PubMed  Google Scholar 

  • Buira SP, Dentesano G, Albasanz JL, Moreno J, Martin M, Ferrer I, Barrachina M (2010b) DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. J Neurochem 115:283–295

    Article  CAS  PubMed  Google Scholar 

  • Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, Mengod G, Ernfors P, Alberch J (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci 24:7727–7739

    Article  CAS  PubMed  Google Scholar 

  • Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66:525–539

    Article  CAS  PubMed  Google Scholar 

  • Cepeda C, Cummings DM, Hickey MA, Kleiman-Weiner M, Chen JY, Watson JB, Levine MS (2010) Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington’s disease: exercise, adenosine receptors and ampakines. PLoS Curr 2:1182

    Article  Google Scholar 

  • Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci 23:961–969

    CAS  PubMed  Google Scholar 

  • Cha JH (2007) Transcriptional signatures in Huntington’s disease. Prog Neurobiol 83:228–248

    Article  CAS  PubMed  Google Scholar 

  • Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB Jr, Davies SW, Bates GP, Young AB (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci 354:981–989

    Article  CAS  PubMed  Google Scholar 

  • Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4:299–309

    Article  CAS  PubMed  Google Scholar 

  • Charalambous C, Gsandtner I, Keuerleber S, Milan-Lobo L, Kudlacek O, Freissmuth M, Zezula J (2008) Restricted collision coupling of the A2A receptor revisited: evidence for physical separation of two signaling cascades. J Biol Chem 283:9276–9288

    Article  CAS  PubMed  Google Scholar 

  • Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72:1890–1898

    Article  CAS  PubMed  Google Scholar 

  • Chiang MC, Chen HM, Lai HL, Chen HW, Chou SY, Chen CM, Tsai FJ, Chern Y (2009) The A2A adenosine receptor rescues the urea cycle deficiency of Huntington’s disease by enhancing the activity of the ubiquitin-proteasome system. Hum Mol Genet 18:2929–2942

    Article  CAS  PubMed  Google Scholar 

  • Chiang MC, Lee YC, Huang CL, Chern Y (2005) cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J Biol Chem 280:14331–14340

    Article  CAS  PubMed  Google Scholar 

  • Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H (2008) Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33:2791–2800

    Article  CAS  PubMed  Google Scholar 

  • Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407–1420

    Article  CAS  PubMed  Google Scholar 

  • Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS et al (2005) CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model. J Neurochem 93:310–320

    Article  CAS  PubMed  Google Scholar 

  • Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F (2008) Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 213:163–170

    Article  CAS  PubMed  Google Scholar 

  • Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, Li XJ, Saudou F, Humbert S (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 27:2124–2134

    Article  CAS  PubMed  Google Scholar 

  • Cornelis MC, El-Sohemy A, Campos H (2007) Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 86:240–244

    CAS  PubMed  Google Scholar 

  • Corradetti R, Lo Conte G, Moroni F, Passani MB, Pepeu G (1984) Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol 104:19–26

    Article  CAS  PubMed  Google Scholar 

  • Corsi C, Melani A, Bianchi L, Pedata F (2000) Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 11:2591–2595

    Article  CAS  PubMed  Google Scholar 

  • Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F (1999) Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport 10:687–691

    Article  CAS  PubMed  Google Scholar 

  • Dai SS, Zhou YG, Li W, An JH, Li P, Yang N, Chen XY, Xiong RP, Liu P, Zhao Y et al (2010) Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 30:5802–5810

    Article  CAS  PubMed  Google Scholar 

  • de Mendonca A, Ribeiro JA (2000) Long-term potentiation observed upon blockade of adenosine A1 receptors in rat hippocampus is N-methyl-D-aspartate receptor-dependent. Neurosci Lett 291:81–84

    Article  PubMed  Google Scholar 

  • de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, van Leeuwen FW (2004) Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 13:1803–1813

    Article  PubMed  Google Scholar 

  • del Toro D, Canals JM, Gines S, Kojima M, Egea G, Alberch J (2006) Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci 26:12748–12757

    Article  PubMed  CAS  Google Scholar 

  • del Toro D, Xifro X, Pol A, Humbert S, Saudou F, Canals JM, Alberch J (2010) Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington’s disease. J Neurochem 115:153–167

    Article  PubMed  CAS  Google Scholar 

  • Dhaenens CM, Burnouf S, Simonin C, Van Brussel E, Duhamel A, Defebvre L, Duru C, Vuillaume I, Cazeneuve C, Charles P et al (2009) A genetic variation in the ADORA2A gene modifies age at onset in Huntington’s disease. Neurobiol Dis 35:474–476

    Article  CAS  PubMed  Google Scholar 

  • Di Maria E, Marasco A, Tartari M, Ciotti P, Abbruzzese G, Novelli G, Bellone E, Cattaneo E, Mandich P (2006) No evidence of association between BDNF gene variants and age-at-onset of Huntington’s disease. Neurobiol Dis 24:274–279

    Article  PubMed  CAS  Google Scholar 

  • Diogenes MJ, Fernandes CC, Sebastiao AM, Ribeiro JA (2004) Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24:2905–2913

    Article  CAS  PubMed  Google Scholar 

  • Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington’s disease mice. Neurobiol Dis 28:197–205

    Article  CAS  PubMed  Google Scholar 

  • Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J Neurosci 27:3571–3583

    Article  CAS  PubMed  Google Scholar 

  • Dragatsis I, Efstratiadis A, Zeitlin S (1998) Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125:1529–1539

    CAS  PubMed  Google Scholar 

  • Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31–55

    Article  CAS  PubMed  Google Scholar 

  • Duru C, Simonin C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C et al (2011) Caffeine is a modifier of age at onset in Huntington’s disease. In: Movement disorders society meeting, Toronto

    Google Scholar 

  • Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet 19:3053–3067

    Article  CAS  PubMed  Google Scholar 

  • Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA (2007) Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci 27:3768–3779

    Article  CAS  PubMed  Google Scholar 

  • Fan MM, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington’s disease. Prog Neurobiol 81:272–293

    Article  CAS  PubMed  Google Scholar 

  • Ferrante A, Martire A, Armida M, Chiodi V, Pezzola A, Potenza RL, Domenici MR, Popoli P (2010) Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington’s disease mice. Brain Res 1323:184–191

    Article  CAS  PubMed  Google Scholar 

  • Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem 88:538–544

    Article  CAS  PubMed  Google Scholar 

  • Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133

    CAS  PubMed  Google Scholar 

  • Fredholm BB, Chern Y, Franco R, Sitkovsky M (2007) Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol 83:263–276

    Article  CAS  PubMed  Google Scholar 

  • Fredholm BB, Dunwiddie TV (1988) How does adenosine inhibit transmitter release? Trends Pharmacol Sci 9:130–134

    Article  CAS  PubMed  Google Scholar 

  • Galluzzo M, Pintor A, Pezzola A, Grieco R, Borsini F, Popoli P (2008) Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535. Eur J Pharmacol 579:149–152

    Article  CAS  PubMed  Google Scholar 

  • Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138

    Article  CAS  PubMed  Google Scholar 

  • Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15:133–139

    Article  CAS  PubMed  Google Scholar 

  • Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington’s disease phenotypes in mice. J Neurochem 105:369–379

    Article  CAS  PubMed  Google Scholar 

  • Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis 17:77–88

    Article  CAS  PubMed  Google Scholar 

  • Giralt A, Friedman HC, Caneda-Ferron B, Urban N, Moreno E, Rubio N, Blanco J, Peterson A, Canals JM, Alberch J (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington’s disease. Gene Ther 17:1294–1308

    Article  CAS  PubMed  Google Scholar 

  • Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97:505–519

    Article  CAS  PubMed  Google Scholar 

  • Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, Dietrich P, Volvert ML, Guillemot F, Dragatsis I et al (2010) Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 67:392–406

    Article  CAS  PubMed  Google Scholar 

  • Gotoh L, Mitsuyasu H, Kobayashi Y, Oribe N, Takata A, Ninomiya H, Stanton VP Jr, Springett GM, Kawasaki H, Kanba S (2009) Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatr Genet 19:328–335

    Article  PubMed  Google Scholar 

  • Gourfinkel-An I, Cancel G, Trottier Y, Devys D, Tora L, Lutz Y, Imbert G, Saudou F, Stevanin G, Agid Y et al (1997) Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann Neurol 42:712–719

    Article  CAS  PubMed  Google Scholar 

  • Gsandtner I, Charalambous C, Stefan E, Ogris E, Freissmuth M, Zezula J (2005) Heterotrimeric G protein-independent signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A adenosine receptor is necessary for sustained activation of the ERK/MAP kinase pathway. J Biol Chem 280:31898–31905

    Article  CAS  PubMed  Google Scholar 

  • Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol 39:385–389

    Article  CAS  PubMed  Google Scholar 

  • Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23:190–197

    Article  CAS  PubMed  Google Scholar 

  • Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington’s disease. Neurobiol Dis 17:455–461

    Article  CAS  PubMed  Google Scholar 

  • Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29:558–565

    Article  CAS  PubMed  Google Scholar 

  • Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H (2005) Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet 139B:42–44

    Article  CAS  PubMed  Google Scholar 

  • Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ, Chen WP, Shen YC, Chen HM, Chen JB et al (2011) A new drug design targeting the adenosinergic system for Huntington’s disease. PLoS One 6:e20934

    Article  CAS  PubMed  Google Scholar 

  • Huang QY, Wei C, Yu L, Coelho JE, Shen HY, Kalda A, Linden J, Chen JF (2006) Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J Neurosci 26:11371–11378

    Article  CAS  PubMed  Google Scholar 

  • Jacquard C, Trioulier Y, Cosker F, Escartin C, Bizat N, Hantraye P, Cancela JM, Bonvento G, Brouillet E (2006) Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J 20:1021–1023

    Article  CAS  PubMed  Google Scholar 

  • Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology 50:1357–1365

    Article  CAS  PubMed  Google Scholar 

  • Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet 19:3919–3935

    Article  CAS  PubMed  Google Scholar 

  • Kishikawa S, Li JL, Gillis T, Hakky MM, Warby S, Hayden M, MacDonald ME, Myers RH, Gusella JF (2006) Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington’s disease. Neurobiol Dis 24:280–285

    Article  CAS  PubMed  Google Scholar 

  • Lee FS, Chao MV (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 98:3555–3560

    Article  CAS  PubMed  Google Scholar 

  • Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Bjorkhem I et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease. Brain 131:2851–2859

    Article  PubMed  Google Scholar 

  • LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295–302

    Article  CAS  PubMed  Google Scholar 

  • Li XX, Nomura T, Aihara H, Nishizaki T (2001) Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci 68:1343–1350

    Article  CAS  PubMed  Google Scholar 

  • Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP (2001) Impaired glutamate uptake in the R6 Huntington’s disease transgenic mice. Neurobiol Dis 8:807–821

    Article  CAS  PubMed  Google Scholar 

  • Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G et al (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum Mol Genet 9:1259–1271

    Article  CAS  PubMed  Google Scholar 

  • Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, Simmons DA (2007) Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. J Neurosci 27:4424–4434

    Article  CAS  PubMed  Google Scholar 

  • Maglione V, Cannella M, Martino T, De Blasi A, Frati L, Squitieri F (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 393:27–30

    Article  CAS  PubMed  Google Scholar 

  • Maglione V, Giallonardo P, Cannella M, Martino T, Frati L, Squitieri F (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington’s disease. Am J Med Genet B Neuropsychiatr Genet 139B:101–105

    Article  CAS  PubMed  Google Scholar 

  • Martire A, Ferrante A, Potenza RL, Armida M, Ferretti R, Pezzola A, Domenici MR, Popoli P (2010) Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington’s disease mice. Neurobiol Dis 37:99–105

    Article  CAS  PubMed  Google Scholar 

  • McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76:550–557

    Article  CAS  PubMed  Google Scholar 

  • Messmer K, Reynolds GP (1998) Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington’s disease. Neurosci Lett 241:53–56

    Article  CAS  PubMed  Google Scholar 

  • Metzger S, Saukko M, Van Che H, Tong L, Puder Y, Riess O, Nguyen HP (2010) Age at onset in Huntington’s disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. Hum Genet 128:453–459

    Article  CAS  PubMed  Google Scholar 

  • Mievis S, Blum D, Ledent C (2011) A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington’s disease. Neurobiol Dis 41:570–576

    Article  CAS  PubMed  Google Scholar 

  • Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773–30782

    Article  CAS  PubMed  Google Scholar 

  • Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 11:320–339

    Article  CAS  PubMed  Google Scholar 

  • Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR et al (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron 65:178–190

    Article  CAS  PubMed  Google Scholar 

  • Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K, Popoli P (2007) Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 66:363–371

    Article  CAS  PubMed  Google Scholar 

  • Morelli M, Carta AR, Jenner P (2009) Adenosine A2A receptors and Parkinson’s disease. Handb Exp Pharmacol 589–615

    Google Scholar 

  • Nishizaki T, Nagai K, Nomura T, Tada H, Kanno T, Tozaki H, Li XX, Kondoh T, Kodama N, Takahashi E et al (2002) A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 39:133–147

    Article  CAS  PubMed  Google Scholar 

  • Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF (2009) Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci 12:872–878

    Article  CAS  PubMed  Google Scholar 

  • Orru M, Bakesova J, Brugarolas M, Quiroz C, Beaumont V, Goldberg SR, Lluis C, Cortes A, Franco R, Casado V et al (2011) Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One 6:e16088

    Article  CAS  PubMed  Google Scholar 

  • Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132:3152–3164

    Article  PubMed  Google Scholar 

  • Palmer TM, Stiles GL (1995) Adenosine receptors. Neuropharmacology 34:683–694

    Article  CAS  PubMed  Google Scholar 

  • Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5:731–736

    CAS  PubMed  Google Scholar 

  • Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638–1643

    Article  CAS  PubMed  Google Scholar 

  • Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington’s disease mouse model. Exp Neurol 210:154–163

    Article  CAS  PubMed  Google Scholar 

  • Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36:315–320

    Article  CAS  PubMed  Google Scholar 

  • Pinna A (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 18:1619–1631

    Article  CAS  PubMed  Google Scholar 

  • Pintor A, Galluzzo M, Grieco R, Pezzola A, Reggio R, Popoli P (2004) Adenosine A 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89:152–156

    Article  CAS  PubMed  Google Scholar 

  • Pintor A, Quarta D, Pezzola A, Reggio R, Popoli P (2001) SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur J Pharmacol 421:177–180

    Article  CAS  PubMed  Google Scholar 

  • Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp 32:258–270

    Article  PubMed  Google Scholar 

  • Popoli P, Betto P, Reggio R, Ricciarello G (1995) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287:215–217

    Article  CAS  PubMed  Google Scholar 

  • Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y (2008) A critical evaluation of adenosine A2A receptors as potentially “druggable” targets in Huntington’s disease. Curr Pharm Des 14:1500–1511

    Article  CAS  PubMed  Google Scholar 

  • Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington’s disease. Prog Neurobiol 81:331–348

    Article  CAS  PubMed  Google Scholar 

  • Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pezzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F et al (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22:1967–1975

    CAS  PubMed  Google Scholar 

  • Pousinha PA, Diogenes MJ, Ribeiro JA, Sebastiao AM (2006) Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci Lett 404:143–147

    Article  CAS  PubMed  Google Scholar 

  • Quiroz C, Lujan R, Uchigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA et al (2009) Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 9:1321–1344

    Article  CAS  PubMed  Google Scholar 

  • Rebola N, Simoes AP, Canas PM, Tome AR, Andrade GM, Barry CE, Agostinho PM, Lynch MA, Cunha RA (2011) Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 117:100–111

    Article  CAS  PubMed  Google Scholar 

  • Reiner A, Medina L, Veenman CL (1998) Structural and functional evolution of the basal ganglia in vertebrates. Brain Res Brain Res Rev 28:235–285

    Article  CAS  PubMed  Google Scholar 

  • Rogers PJ, Hohoff C, Heatherley SV, Mullings EL, Maxfield PJ, Evershed RP, Deckert J, Nutt DJ (2010) Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 35:1973–1983

    Article  CAS  PubMed  Google Scholar 

  • Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98

    Article  CAS  PubMed  Google Scholar 

  • Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4:346–369

    CAS  PubMed  Google Scholar 

  • Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161–172

    CAS  PubMed  Google Scholar 

  • Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, Calamandrei G (2007) Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington’s disease. Behav Brain Res 176:216–221

    Article  CAS  PubMed  Google Scholar 

  • Schiffmann SN, Vanderhaeghen JJ (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080–1087

    CAS  PubMed  Google Scholar 

  • Schwab C, Klegeris A, McGeer PL (2010) Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta 1802:889–902

    Article  CAS  PubMed  Google Scholar 

  • Seo H, Sonntag KC, Isacson O (2004) Generalized brain and skin proteasome inhibition in Huntington’s disease. Ann Neurol 56:319–328

    Article  CAS  PubMed  Google Scholar 

  • Seo H, Sonntag KC, Kim W, Cattaneo E, Isacson O (2007) Proteasome activator enhances survival of Huntington’s disease neuronal model cells. PLoS One 2:e238

    Article  PubMed  CAS  Google Scholar 

  • Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M et al (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871–2880

    Article  CAS  PubMed  Google Scholar 

  • Seward A, Longwell C, Young G, Kostyk S (2010) Caffeine Intake and Disease Characteristics in a Huntington’s Disease Clinic Population. In Fourth Annual Huntington Disease, Clinical Research Symposium (San Diego)

    Google Scholar 

  • Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA (2006) Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 21:392–403

    Article  CAS  PubMed  Google Scholar 

  • Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ (2005) Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171:1001–1012

    Article  CAS  PubMed  Google Scholar 

  • Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Hemachandra Reddy P (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet 20:1438–1455

    Article  CAS  PubMed  Google Scholar 

  • Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G (2009) Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci USA 106:4906–4911

    Article  CAS  PubMed  Google Scholar 

  • Simola N, Morelli M, Pinna A (2008) Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions. Curr Pharm Des 14:1475–1489

    Article  CAS  PubMed  Google Scholar 

  • Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R et al (2007) Neuroprotective effects of synaptic modulation in Huntington’s disease R6/2 mice. J Neurosci 27:12908–12915

    Article  CAS  PubMed  Google Scholar 

  • Stone TW, Ceruti S, Abbracchio MP (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 193:535–587

    Article  CAS  PubMed  Google Scholar 

  • Sugars KL, Brown R, Cook LJ, Swartz J, Rubinsztein DC (2004) Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington’s disease that contributes to polyglutamine pathogenesis. J Biol Chem 279:4988–4999

    Article  CAS  PubMed  Google Scholar 

  • Sun Y, Savanenin A, Reddy PH, Liu YF (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 276:24713–24718

    Article  CAS  PubMed  Google Scholar 

  • Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45:25–32

    Article  CAS  PubMed  Google Scholar 

  • Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L (2009) PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 4:10

    Article  PubMed  CAS  Google Scholar 

  • Taherzadeh-Fard E, Saft C, Wieczorek S, Epplen JT, Arning L (2010) Age at onset in Huntington’s disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 11:435–439

    Article  CAS  PubMed  Google Scholar 

  • Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007) Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 130:1759–1766

    Article  PubMed  Google Scholar 

  • Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, Bates G, Cattaneo E, Abbracchio MP (2006) Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis 23:44–53

    Article  CAS  PubMed  Google Scholar 

  • Tebano MT, Martire A, Potenza RL, Gro C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P (2008) Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem 104:279–286

    CAS  PubMed  Google Scholar 

  • Tebano MT, Pintor A, Frank C, Domenici MR, Martire A, Pepponi R, Potenza RL, Grieco R, Popoli P (2004) Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. J Neurosci Res 77:100–107

    Article  CAS  PubMed  Google Scholar 

  • The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983

    Article  Google Scholar 

  • Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC, Mandel JL (1995) Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form. Nat Genet 10:104–110

    Article  CAS  PubMed  Google Scholar 

  • Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E (2007a) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 16:2187–2198

    Article  CAS  PubMed  Google Scholar 

  • Valenza M, Cattaneo E (2006) Cholesterol dysfunction in neurodegenerative diseases: is Huntington’s disease in the list? Prog Neurobiol 80:165–176

    Article  CAS  PubMed  Google Scholar 

  • Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O et al (2010) Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J Neurosci 30:10844–10850

    Article  CAS  PubMed  Google Scholar 

  • Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, Cattaneo E (2007b) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis 28:133–142

    Article  CAS  PubMed  Google Scholar 

  • Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J Neurosci 25:9932–9939

    Article  CAS  PubMed  Google Scholar 

  • Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, Mariotti C, Cattabriga E, Cattabeni F, Borea PA, Squitieri F et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. FASEB J 17:2148–2150

    CAS  PubMed  Google Scholar 

  • Varani K, Bachoud-Levi AC, Mariotti C, Tarditi A, Abbracchio MP, Gasperi V, Borea PA, Dolbeau G, Gellera C, Solari A et al (2007) Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington’s disease stages. Neurobiol Dis 27:36–43

    Article  CAS  PubMed  Google Scholar 

  • Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, Abbracchio MP, Cattaneo E (2001) Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J 15:1245–1247

    CAS  PubMed  Google Scholar 

  • Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384

    Article  CAS  PubMed  Google Scholar 

  • Wagner AK, Miller MA, Scanlon J, Ren D, Kochanek PM, Conley YP (2010) Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res 90:259–272

    Article  CAS  PubMed  Google Scholar 

  • Walker FO (2007) Huntington’s disease. Lancet 369:218–228

    Article  CAS  PubMed  Google Scholar 

  • Wei CJ, Li W, Chen JF (2011) Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 1808:1358–1379

    Article  CAS  PubMed  Google Scholar 

  • Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD et al (2006) Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab 4:349–362

    Article  CAS  PubMed  Google Scholar 

  • Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci USA 104:17210–17215

    Article  CAS  PubMed  Google Scholar 

  • Wu J, Lee MR, Kim T, Johng S, Rohrback S, Kang N, Choi DS (2011) Regulation of ethanol-sensitive EAAT2 expression through adenosine A1 receptor in astrocytes. Biochem Biophys Res Commun 406:47–52

    Article  CAS  PubMed  Google Scholar 

  • Wu LL, Fan Y, Li S, Li XJ, Zhou XF (2010) Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J Biol Chem 285:5614–5623

    Article  CAS  PubMed  Google Scholar 

  • Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci 30:14708–14718

    Article  CAS  PubMed  Google Scholar 

  • Yang A, Palmer AA, de Wit H (2010) Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 211:245–257

    Article  CAS  Google Scholar 

  • Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 33:849–860

    Article  CAS  PubMed  Google Scholar 

  • Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 81:294–330

    Article  CAS  PubMed  Google Scholar 

  • Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5:311–322

    Article  CAS  PubMed  Google Scholar 

  • Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498

    Article  CAS  PubMed  Google Scholar 

  • Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T et al (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76–83

    Article  CAS  PubMed  Google Scholar 

  • Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90:905–981

    Article  CAS  PubMed  Google Scholar 

  • Zuchora B, Turski WA, Wielosz M, Urbanska EM (2001) Protective effect of adenosine receptor agonists in a new model of epilepsy–seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice. Neurosci Lett 305:91–94

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm, U837, Place de Verdun, Lille, 59045, France

    David Blum, Sylvie Burnouf & Bernard Sablonnière

  2. Jean-Pierre Aubert Reserach Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université Lille-Nord de France, UDSL, Lille, France

    David Blum, Sylvie Burnouf & Bernard Sablonnière

  3. CHRU-Lille, Lille, France

    David Blum, Sylvie Burnouf & Bernard Sablonnière

  4. Section of Central Nervous System Pharmacology, Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, Rome, 299, Italy

    Alberto Martire & Patrizia Popoli

  5. Department of Neurology, Amiens University Hospital, Amiens, France

    Pierre Krystkowiak

  6. CNRS UMR 8160, Amiens, France

    Pierre Krystkowiak

  7. IRIBHM, Université Libre de Bruxelles, Brussels, Belgium

    Catherine Ledent

  8. Department of Neurology and Institute of Pharmacology and Neurosciences, Institute of Molecular Medicine and Faculty of Medicine of Lisbon, University of Lisbon, Lisbon, Portugal

    Luisa V. Lopes

Authors
  1. David Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Martire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvie Burnouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernard Sablonnière
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Krystkowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Catherine Ledent
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luisa V. Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrizia Popoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to David Blum or Patrizia Popoli .

Editor information

Editors and Affiliations

  1. Trinity College, 300 Summit Street, LSC 208, Hartford, 06106, USA

    Susan Masino

  2. Legacy Research Institute, Portland, OR,, 1225 NE 2nd Avenue, Portland, 97232, USA

    Detlev Boison

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Blum, D. et al. (2013). Adenosine Receptors in Huntington’s Disease. In: Masino, S., Boison, D. (eds) Adenosine. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3903-5_20

Download citation

Publish with us

Policies and ethics

Search

Navigation